A Super-Enhancer Driven by FOSL1 Controls miR-21-5p Expression in Head and Neck Squamous Cell Carcinoma.
FOSL1
head and neck squamous cell carcinoma
metastasis
miR-21-5p
super enhancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
01
2021
accepted:
25
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
MiR-21-5p is one of the most common oncogenic miRNAs that is upregulated in many solid cancers by inhibiting its target genes at the posttranscriptional level. However, the upstream regulatory mechanisms of miR-21-5p are still not well documented in cancers. Here, we identify a super-enhancer associated with the
Identifiants
pubmed: 33937067
doi: 10.3389/fonc.2021.656628
pmc: PMC8085558
doi:
Types de publication
Journal Article
Langues
eng
Pagination
656628Informations de copyright
Copyright © 2021 Wan, Hoyle, Xie, Wang, Cai, Zhang, Ma, Xiong, Xu, Huang, Liu, Li and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cells. 2020 Dec 31;10(1):
pubmed: 33396240
Cell Cycle. 2010 Mar 1;9(5):923-9
pubmed: 20160498
Circulation. 2019 Jun 18;139(25):2857-2876
pubmed: 30947518
Cancer Res. 2011 May 1;71(9):3387-99
pubmed: 21385897
Cell Rep. 2014 Oct 9;9(1):234-247
pubmed: 25263550
Arch Toxicol. 2014 Sep;88(9):1651-68
pubmed: 25085708
RNA Biol. 2011 Sep-Oct;8(5):706-13
pubmed: 21712654
Cancer. 2021 Apr 15;127(8):1238-1245
pubmed: 33320343
Clin Cancer Res. 2019 May 1;25(9):2860-2873
pubmed: 30723145
Cell. 2017 Mar 9;168(6):1000-1014.e15
pubmed: 28283057
Cancer Metastasis Rev. 2017 Sep;36(3):525-545
pubmed: 28836104
J BUON. 2020 Jan-Feb;25(1):357-366
pubmed: 32277655
Hepatology. 2019 Jun;69(6):2502-2517
pubmed: 30723918
BMC Oral Health. 2020 Jan 29;20(1):24
pubmed: 31996191
Clin Cancer Res. 2021 Feb 1;27(3):831-842
pubmed: 33148669
Nat Rev Mol Cell Biol. 2015 Mar;16(3):144-54
pubmed: 25650801
Cancer Lett. 2019 Aug 1;456:40-48
pubmed: 31055111
PeerJ. 2020 Sep 15;8:e9701
pubmed: 32983633
J Oral Pathol Med. 2015 Nov;44(10):792-800
pubmed: 25482863
Bioinformatics. 2014 Aug 1;30(15):2237-8
pubmed: 24651967
Genomics. 2021 Jan;113(1 Pt 1):135-141
pubmed: 33279650
Mol Ther Oncolytics. 2020 May 26;18:47-57
pubmed: 32637580
Gastroenterology. 2018 Jun;154(8):2137-2151.e1
pubmed: 29454790
Cancer Biother Radiopharm. 2019 Apr;34(3):189-195
pubmed: 30628842
Oncotarget. 2016 Oct 4;7(40):65744-65757
pubmed: 27582550
Oncol Lett. 2017 Feb;13(2):554-566
pubmed: 28356929
Sci Signal. 2013 Apr 30;6(273):ra28.1-13, S0-15
pubmed: 23633675
Cell Stem Cell. 2017 May 4;20(5):621-634.e6
pubmed: 28285905
Nat Rev Cancer. 2016 Aug;16(8):483-93
pubmed: 27364481
Mol Med Rep. 2016 May;13(5):4315-20
pubmed: 27035337
Theranostics. 2020 Jan 1;10(3):1433-1453
pubmed: 31938073
J Mol Biol. 2008 May 2;378(3):492-504
pubmed: 18384814
Drug Dev Res. 2015 Sep;76(6):270-7
pubmed: 26082192
Oncotarget. 2017 Mar 28;8(13):21954-21973
pubmed: 28423539
Cell Prolif. 2018 Dec;51(6):e12521
pubmed: 30182381
Mol Ther Nucleic Acids. 2020 Jun 5;20:409-420
pubmed: 32244168
Cell Death Dis. 2020 Dec 14;11(12):1067
pubmed: 33318473
J Cell Physiol. 2020 Nov;235(11):8799-8811
pubmed: 32342519
Oncol Rep. 2014 Nov;32(5):2283-9
pubmed: 25175929
Oral Oncol. 2012 Aug;48(8):686-91
pubmed: 22425712
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902